Universal mRNA Influenza Vaccine Achieves 94% Efficacy in Multi-Center Phase III Trial
A single quadrivalent dose provides durable cross-strain neutralizing antibodies against emerging seasonal and avian strains.
Executive Briefing
Clinical results published in the New England Journal of Medicine confirm that a universal mRNA vaccine candidate affords comprehensive protection across historically evasive influenza lineages.
BOSTON — A watershed moment in preventive medicine arrived this week as phase III clinical trial data encompassing 32,000 adult volunteers confirmed that an experimental universal mRNA influenza vaccine confers 94.2% efficacy against laboratory-confirmed symptomatic infection.
Unlike traditional seasonal flu jabs which must be reformulated annually based on predictive epidemiological forecasts, the universal formulation targets invariant stalk regions of the hemagglutinin surface glycoprotein.
"For decades, we have been forced to play an evolutionary guessing game against rapid antigen mutation," said Dr. Arthur Pendelton, chief of immunology at the Boston BioResearch Institute. "By anchoring our antibody response to conserved viral architecture, we have achieved a durable umbrella of immunological defense."
Public health regulators in the United States and European Union have initiated rolling reviews, with potential widespread distribution targeted prior to the 2027 winter respiratory season.
Video Dispatch
Dispatch Photo Gallery
Financial analyst and senior business correspondent covering global equities and macroeconomic policy.
Related Coverage
